Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Fleming, Jo Nadine ^a   Shulman, Howard M ^a,b   Nash, Richard A ^b   Johnson, Pamela Y ^b   Wight, Thomas N ^b   Gown, Allen ^c   Schwartz, Stephen M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Benaroya Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULAR ENDOTHELIAL CADHERIN; VON WILLEBRAND FACTOR;

ARTICLE; CELL HYPERPLASIA; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTIMA; MICROVASCULATURE; PHENOTYPE; SKIN BIOPSY; SKIN BLOOD VESSEL; SKIN CAPILLARY; SKIN CELL; SKIN DISEASE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; CHRONIC DISEASE; ENDOTHELIUM; GRAFT VERSUS HOST REACTION; PATHOLOGY;

CHRONIC DISEASE; ENDOTHELIUM; GRAFT VS HOST DISEASE; HUMANS; PHENOTYPE; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 67650908413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006203     Document Type: Article

References (45)

1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee S, et al. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11: 945-956.
2. Hymes SR, Turner M, Champlin R, Couriel D (2006) Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 12: 1101-1113.
3. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. (2006) Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 12: 31-47.
4. Shlomchik WD (2007) Graft-versus-host Disease. Nat Rev Immunol 7: 340-352.
5. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC (2002) Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168: 3088-3098.
6. Lakos G, Takagawa S, Varga J (2004) AnimalModels of Scleroderma. In: Perl A, ed. Autoimmunity: Methods and Protocols. Totowa: Humana. pp 377-393.
7. Sgonc R, Dietrich H, Sieberer C, Wick G, Christner PJ, et al. (1999) Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis Rheum 42: 581-584.
8. Jimenez SA, Christner PJ (2002) Murine animal models of systemic sclerosis. Curr Opin Rheumatol 14: 671-680.
9. Biedermann BC, et al. (2002) Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359: 2078-2083.
10. Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y, et al. (2004) Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 33: 1143-1150.
11. Socie G, Mary JY, Lemann M, Daneshpouy M, Guardiola P, Meignin V, et al. (2004) Prognostic value of apoptotic cells and infiltrating neutrophils in graftversus- host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood 103: 50-57.
12. Fleming J, Nash RA, McLeod DO, et al. (2008) Capillary Regeneration in Scleroderma; Stem Cell Therapy Reverses Phenotype? PLoS ONE.
13. Wallez Y, Vilgrain I, Huber P (2006) Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16: 55-59.
14. D'Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fiftyeight matched controls. Am J Med 46: 428-440.
15. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675-694.
16. Nash RA, et al. (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term followup of the U.S. multicenter pilot study. Blood 110: 1388-1396.
17. Janin A, Deschaumes C, Daneshpouy, Estaquier J, Micic-Polianski J, et al. (2002) CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood 99: 2940-2947.
18. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN (1994) Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 144: 962-974.
19. Brat DJ, Van Meir EG (2001) Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 158: 789-796.
20. Detmar M, et al. (1998) Increased Microvacular density and enhanced leukocyte rolling in the skin of VEGF transgeinic mice. J Invest Dermatol 111: 1-6.
21. Larcher F, Murillas R, Bolontrade M, Conti C, Jorcano JL (1998) VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene Volume 17: 303-311.
22. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, Park KS, Seo YI, Kim WU, Park SH, Cho CS (2003) Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 30: 1529-1533.
23. Shiao SL, Kirkiles-Smith NC, Shepherd BR, McNiff JM, Carr EJ, et al. (2007) Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol 179: 4397-4404.
24. Shimura K, Ashihara E, Shimazaki C, Matsunaga S, Taniguchi K, et al. (2008) Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease. Biol Blood Marrow Transplant 14: 426-437.
25. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, et al. (1996) An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88: 3230-3239.
26. Sackstein R (2006) A Revision of Billingham's Tenets: The Central Role of Lymphocyte Migration in Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 12: 2-8.
27. Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM (2008) Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 6: 928-934.
28. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD (1989) von Willebrand factor is an acute phase reactant in man. Thromb Res 53: 387-394.
29. Fernandez-Mateos P, Cailleau A, Henry S, Costache M, Elmgren A, et al. (1998) Point mutations and deletion responsible for the Bombay H null and the Reunion H weak blood groups. Vox Sang 75: 37-46.
30. Jass JR, Walsh MD (2001) Altered mucin expression in the gastrointestinal tract: a review. J Cell Mol Med 5: 327-351.
31. Alva JA, Zovein AC, Monvoisin A, Murphy T, Salazar A, et al. (2006) VECadherin- Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn 235: 759-767.
32. Mitchell RN, Libby P (2007) Vascular remodeling in transplant vasculopathy. Circ Res 100: 967-978.
33. Liu X, et al. (2005) Paclitaxel Modulates TGFβ Signaling in Scleroderma Skin Grafts in Immunodeficient Mice. PLoS Med 2: e354.
34. McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, Bona C (2001) Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 116: 136-143.
35. Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200: 500-503.
36. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83: 4167-4171.
37. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, Chen Y, Venstrom K, Dou X, Ponticos M, Black C, Bernabeu C, Jackman JK, Findell PR, Connolly MK (2002) Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 46: 1857-1865.
38. Kaur H, Chaurasia SS, de Medeiros FW, Agrawal V, Salomao MQ, et al. (2008) Corneal stroma PDGF blockade and myofibroblast development. Exp Eye Res 88: 960-965.
39. Pan D, Zhe X, Jakkaraju S, Taylor GA, Schuger L (2002) P311 induces a TGF-beta1-independent, nonfibrogenic myofibroblast phenotype. J Clin Invest 110: 1349-1358.
40. Kielty CM, Whittaker SP, Grant ME, Shuttleworth CA (1992) Attachment of human vascular smooth muscle cells to intact microfibrillar assemblies of collagen VI and fibrillin. J Cell Sci 103: 445-451.
41. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC (2007) Angiotensin II type 1 receptor blockade attenuates TGF-[beta]-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
42. Svegliati Baroni S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, et al. (2006) Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis. NEJM 354: 2667-2676.
43. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, et al. (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110: 237-241.
44. Ratanatharathorn V, Ayash L, Reynolds C, et al. (2003) Treatment of Chronic Graft-versus-Host Disease with Anti-CD20 Chimeric Monoclonal Antibody. Biol Blood Marrow Transplant 9: 505-511.
45. Nash RA, McSweeney PA, Nelson JL, Wener M, Georges GE, Langston AA, Shulman H, Sullivan KM, Lee J, Henstorf G, Storb R, Furst DE (2006) Allogeneic marrow transplantation in patients with severe systemic sclerosis: Resolution of dermal fibrosis. Arthritis Rheum 54: 1982-1986.